{"id":"placebo-for-risankizumab-sc","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo contains no active pharmaceutical ingredient and serves as the control arm in phase 3 trials of risankizumab subcutaneous formulation. It allows researchers to isolate the true therapeutic effect of risankizumab by comparing patient outcomes between the active drug and an inert comparator administered via the same route.","oneSentence":"This is a placebo control used in clinical trials to compare against risankizumab, an IL-23 inhibitor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:26.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in risankizumab phase 3 trials (likely psoriasis, Crohn's disease, or ulcerative colitis based on risankizumab's development program)"}]},"trialDetails":[{"nctId":"NCT03398135","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-28","conditions":"Ulcerative Colitis (UC)","enrollment":1242},{"nctId":"NCT06063967","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-11-15","conditions":"Crohn's Disease","enrollment":289},{"nctId":"NCT03671148","phase":"PHASE3","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-03-07","conditions":"Psoriatic Arthritis (PsA)","enrollment":444},{"nctId":"NCT03105102","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-09","conditions":"Crohn's Disease","enrollment":1336},{"nctId":"NCT03398148","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-03-07","conditions":"Ulcerative Colitis (UC)","enrollment":1558},{"nctId":"NCT04713592","phase":"PHASE3","title":"Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-02-26","conditions":"Psoriasis","enrollment":174},{"nctId":"NCT03926169","phase":"PHASE2","title":"A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-03","conditions":"Hidradenitis Suppurativa","enrollment":243},{"nctId":"NCT03105128","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-10","conditions":"Crohn's Disease","enrollment":931},{"nctId":"NCT03104413","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-18","conditions":"Crohn's Disease","enrollment":618},{"nctId":"NCT03706040","phase":"PHASE2","title":"A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-12-27","conditions":"Dermatitis","enrollment":172},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT03875482","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-05-13","conditions":"Psoriasis","enrollment":157},{"nctId":"NCT03518047","phase":"PHASE3","title":"Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-19","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02047110","phase":"PHASE2","title":"BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-28","conditions":"Ankylosing Spondylitis (AS)","enrollment":159},{"nctId":"NCT02719171","phase":"PHASE2","title":"BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04","conditions":"Arthritis, Psoriatic","enrollment":185},{"nctId":"NCT03000075","phase":"PHASE2","title":"BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-02","conditions":"Psoriasis","enrollment":182},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Risankizumab SC","genericName":"Placebo for Risankizumab SC","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control used in clinical trials to compare against risankizumab, an IL-23 inhibitor. Used for Control arm in risankizumab phase 3 trials (likely psoriasis, Crohn's disease, or ulcerative colitis based on risankizumab's development program).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}